Medicines Patent Pool

Last updated

The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, [1] based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP). [2]

Contents

Peer-reviewed economics research find that the MPP substantially increased generic drug supplies, especially in countries with stronger patent protection; positive spillover effect to upstream innovation is found in clinical trials and drug product approvals in MPP-related drugs. [3] A related study found that there is an immediate and large increase in licensing of a life-saving drug in low- and middle-income countries when the patent is included in the MPP. [4] An article in The Conversation has summarized issues in the patent system, relevance to LMIC, and the role of the MPP. [5]

Creation

The United Nations-backed Medicines Patent Pool Foundation was established as an independent legal public health entity in July 2010 with the support of Unitaid and has been fully operational since November 2010. [6] [7]

The MPP was established in response to the global HIV/AIDS epidemic, which reached a crisis in LMIC countries that were unable to access essential patented medicines. [6] [8] : 291–324  In 2006, Médecins Sans Frontières (MSF) presented the idea of patent pool to the French Foreign Ministry and UNITAID. [9] The MSF proposal was for an entity that would be dependent on patent holders—"particularly private pharmaceutical companies"—voluntarily agreeing to allow LMIC countries access to their licensed essential medicines. [8] : 291  UNITAID was first developed under the impetus of France in 2006, as a "new drug purchasing facility for HIV, TB and malaria" medications. [9] UNITAID provided "innovative solutions" to "overcome access and innovation barriers for HIV medicines". [9]

It is based on the idea that patents are intended to reward innovation, and that unless licensed, a patent can also prevent the production or sale of affordable, quality-assured generic medicines and the development of novel formulations. [8] : 291–324  The Medicines Patent Pool negotiates with patent holders for licences on HIV, hepatitis C and tuberculosis medicines. These licences permit lower-cost manufacturers to distribute patented medicines in developing countries. Licences also provide the freedom to develop new treatments better suited for resource-limited settings, such as paediatric formulations and fixed-dose combinations. Competition among many manufacturers should bring prices down supporting treatment scale-up.[ citation needed ]

Financing

The Medicines Patent Pool was founded and is funded by Unitaid, a global health initiative that is working with partners to end HIV/AIDS, malaria, tuberculosis and hepatitis C and works to allow more affordable generic medicines to enter the marketplace in low- and middle-income countries. UNITAID provided the initial $US 4 million to set up MPP in 2010. [1] In its first grant phase 2010–2015, the MPP worked exclusively in the HIV field and in December 2014, Unitaid approved another funding package for MPP to continue its HIV work through 2020. In November 2015, the MPP mandate was expanded to hepatitis C and tuberculosis treatment. The Medicines Patent Pool was the first and is now the only independent patent pool that aims to tackle the issue of access to HIV/AIDS, hepatitis C and tuberculosis drugs in low- and middle-income countries. [10]

Structure

The MPP has two governing bodies: a Governance board (i.e.Executive Board) composed of 9 members and an Expert Advisory Group comprising 12 members, it also works with ad hoc experts. [11]

The current Chair of the Governance Board is World Health Organization (WHO)’s former Assistant Director-General for Health Systems and Innovation Marie-Paule Kieny, [12] who succeeded Sigrun Møgedal, chair since March 2016 and Charles Clift, the MPP's founding chairman. Past executive directors includes Charles Gore (2018), Greg Perry (2013–2017), Ellen 't Hoen (2010–2012).[ citation needed ]

Activities

The Medicines Patent Pool negotiates public-health driven licences with patent holders, and sub-licenses to generic manufacturers to encourage the sale of lower-cost generic versions of medicines in over a hundred developing countries.[ citation needed ]

In October 2012, the MPP, Gilead Sciences and the UN National Institutes of Health/University of Illinois were honoured by the Licensing Executives Society (United States and Canada) (LES) for licence agreements that expand access to affordable HIV medicines in developing countries. The LES's annual "Deals of Distinction" Awards are presented to notable intellectual property agreements in five industry sectors and the three parties were recognised for precedence-setting licensing agreements dedicated to improving public health under the Industry-University-Government Interface category. [13]

By 2013, MPP in collaboration with ViiV Healthcare granted 14 voluntary licences generics companies for low-cost versions of abacavir used to treat children living with HIV. [6] As of 2018, the Medicines Patent Pool holds licences for 13 HIV antiretrovirals, an HIV technology platform, 2 hepatitis C direct-acting antivirals and 1 investigational treatment for tuberculosis from patent holders AbbVie, [14] Bristol-Myers Squibb, [15] Gilead Sciences, [16] [17] MSD, [18] ViiV Healthcare, [19] [20] Johns Hopkins University, [21] the University of Liverpool, the US National Institutes of Health [22] and Pharco Pharmaceuticals. [23] The MPP also worked with Janssen [24] and Boehringer Ingelheim [25] to extend their non-assert policies for paediatric darunavir formulations and nevirapine, ensuring that the companies will not assert their patent rights in many more developing countries. The organisation signed an agreement with F. Hoffmann-La Roche [26] to increase access to valganciclovir, an important treatment for an HIV opportunistic infection.

In 2018, the foundation announced a new five-year strategy [27] to improve access to medicines in low- and middle-income countries, which supports international public health goals for HIV, tuberculosis and hepatitis C.

In 2021 deals have been achieved with Merck and Pfizer to allow the manufacture Molnupiravir and Paxlovid without paying royalties in poorer countries. [28] [29]

See also

Related Research Articles

<span class="mw-page-title-main">Lamivudine</span> Chemical compound

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV. Lamivudine is taken by mouth as a liquid or tablet.

The Campaign for Access to Essential Medicines is an international campaign started by Médecins Sans Frontières (MSF) to increase the availability of essential medicines in developing countries. MSF often has difficulties treating patients because the medicines required are too expensive or are no longer produced. Sometimes, the only drugs available are highly toxic or ineffective, and they often have to resort to inadequate testing methods to diagnose patients.

<span class="mw-page-title-main">Emtricitabine/tenofovir</span> Drug combination for HIV/AIDS prophylaxis and treatment

Emtricitabine/tenofovir, sold under the brand name Truvada among others, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains the antiretroviral medications emtricitabine and tenofovir disoproxil. For treatment, it must be used in combination with other antiretroviral medications. For prevention before exposure, in those who are at high risk, it is recommended along with safer sex practices. It does not cure HIV/AIDS. Emtricitabine/tenofovir is taken by mouth.

<span class="mw-page-title-main">Lamivudine/zidovudine</span> Combination drug for HIV

Lamivudine/zidovudine, sold under the brand name Combivir among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains two antiretroviral medications, lamivudine and zidovudine. It is used together with other antiretrovirals. It is taken by mouth twice a day.

<span class="mw-page-title-main">James Love (NGO director)</span>

James Packard Love is the director of Knowledge Ecology International, formerly known as the Consumer Project on Technology, a non-governmental organization with offices in Washington, D.C., and Geneva, that works mainly on matters concerning knowledge management and governance, including intellectual property policy and practice and innovation policy, particularly as they relate to health care and access to knowledge.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Efavirenz/emtricitabine/tenofovir</span> Combination drug for HIV

Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains efavirenz, emtricitabine, and tenofovir disoproxil. It can be used by itself or together with other antiretroviral medications. It is taken by mouth.

<span class="mw-page-title-main">Unitaid</span> Global health initiative

Unitaid is a global health initiative that works with partners to bring about innovations to prevent, diagnose and treat major diseases in low- and middle-income countries, with an emphasis on tuberculosis, malaria, and HIV/AIDS and its deadly co-infections. Founded in 2006, the organization funds the final stages of research and development of new drugs, diagnostics and disease-prevention tools, helps produce data supporting guidelines for their use, and works to allow more affordable generic medicines to enter the marketplace in low- and middle-income countries. Hosted by the World Health Organization (WHO) in Geneva, Unitaid was established by the governments of Brazil, Chile, France, Norway and the United Kingdom.

ViiV Healthcare is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS, with its global headquarters in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company. In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi. According to The Financial Times, the company’s co-ownership structure may change depending on the achievement of certain milestones.

Inder Singh is the founder and CEO of Kinsa. He formerly served as the Executive Vice President of the Clinton Foundation's Clinton Health Access Initiative, a global non-profit organization fighting malaria and other diseases. Singh is known for his work towards improving global health, most notably by brokering the deals announced by former President Clinton that reduced the price of life-saving treatments throughout the developing world, particularly aiding in malaria eradication. Singh is credited with saving over $1 billion in drug costs for developing nations. More than 2.6 million HIV/AIDS patients have received drugs subsidized through CHAI, and more than 30 million malaria patients have received drugs produced at lower cost thanks to CHAI licensing deals.

<span class="mw-page-title-main">Sofosbuvir</span> Chemical compound

Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken by mouth.

The cost of HIV treatment is a complicated issue with an extremely wide range of costs due to varying factors such as the type of antiretroviral therapy and the country in which the treatment is administered. The first line therapy of HIV, or the initial antiretroviral drug regimen for an HIV-infected patient, is generally cheaper than subsequent second-line or third-line therapies. There is also a great variability of drug prices among low, middle, and high income countries. In general, low-income countries have the lowest cost of antiretroviral therapy, while middle- and high-income tend to have considerably higher costs. Certain prices of HIV drugs may be high and difficult to afford due to patent barriers on antiretroviral drugs and slow regulatory approval for drugs, which may lead to indirect consequences such as greater HIV drug resistance and an increased number of opportunistic infections. Government and activist movements have taken efforts to limit the price of HIV drugs.

The United States Intelligence Community (IC) has a long history of producing assessments on infectious diseases. Most of these papers are distributed to government administrators and inform the choices of policymakers. Three of these assessments stand out as analytical products that have had important impact on the awareness, funding and treatment of infectious diseases around the world. The first paper is the National Intelligence Estimate on the Global Infectious Disease Threat, the second paper is the assessment on the Next Wave of HIV/AIDS, and the third paper was the assessment on SARS. This page summarizes the findings of these three papers and provides information about their impact.

A buyers club or buying club is a club organized to pool members' collective buying power, enabling them to make purchases at lower prices than are generally available, or to purchase goods that might be difficult to obtain independently.

<span class="mw-page-title-main">Fostemsavir</span> Chemical compound

Fostemsavir, sold under the brand name Rukobia, is an antiretroviral medication for adults living with HIV/AIDS who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.

Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.

Pharmaceutical innovations are currently guided by a patent system, the patent system protects the innovator of medicines for a period of time. The patent system does not currently stimulate innovation or pricing that provides access to medicine for those who need it the most, It provides for profitable innovation. As of 2014 about $140 Billion is spent on research and development of pharmaceuticals which produces 25–35 new drugs annually. Technology, which is transforming science, medicine, and research tools has increased the speed at which we can analyze data but we currently still must test the products which is a lengthy process. Differences in the performance of medical care may be due to variation in the introduction and circulation of pharmaceutical innovations.

Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.

Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. As of 2019, it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. It is taken by mouth.

<span class="mw-page-title-main">Initiative for Medicines, Access, and Knowledge</span> Nonprofit organization

The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global 501(c)(3) organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public.

References

  1. 1 2 "Patent Pool Implementation Plan" (PDF), UNITAID, 15 December 2009, archived from the original (PDF) on 23 April 2010, retrieved 3 May 2021
  2. ↑ "COVID-19 technology access pool". World Health Organization . 30 June 2020. Retrieved 3 May 2021.
  3. ↑ Wang, Lucy Xiaolu (14 August 2022). "Global Drug Diffusion and Innovation with the Medicines Patent Pool". Journal of Health Economics. 85: 102671. doi:10.1016/j.jhealeco.2022.102671. ISSN   0167-6296. PMID   36030748. S2CID   251576186.
  4. ↑ Galasso, Alberto; Schankerman, Mark (2022). "Licensing Life-Saving Drugs for Developing Countries: Evidence from the Medicines Patent Pool". The Review of Economics and Statistics: 1–40. doi:10.1162/rest_a_01253. ISSN   0034-6535.
  5. ↑ Wang, Lucy Xiaolu (5 December 2022). "Pharma's expensive gaming of the drug patent system is successfully countered by the Medicines Patent Pool, which increases global access and rewards innovation". The Conversation. Retrieved 10 December 2022.
  6. 1 2 3 "ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children: Agreement brings the number of voluntary licenses granted by ViiV Healthcare to 14" (Press release). London, UK. 27 February 2013. Archived from the original on 18 June 2013. Retrieved 3 May 2021.
  7. ↑ "About". Medicines Patent Pool. Retrieved 3 May 2021.
  8. 1 2 3 Cox, Krista L. (24 August 2017). "The Medicines Patent Pool: Promoting Access and Innovation for Life-Saving Medicines Through Voluntary Licenses". Hastings Science and Technology Law Journal. LawArXiv. 4 (2): 35. Retrieved 3 May 2021.
  9. 1 2 3 Childs, Michelle (19 January 2010). "Towards a Patent Pool for HIV Medicines: The Background". The Open AIDS Journal. 4: 33–36. doi: 10.2174/1874613601004020033 . ISSN   1874-6136. PMC   2817875 . PMID   20148090.
  10. ↑ "Medicines Patent Pool Expands To Include Hepatitis C, Tuberculosis". IP Watch. 9 November 2015. Retrieved 9 October 2017.
  11. ↑ "Governance - Medicines Patent Pool". medicinespatentpool.org/staffing-and-governance/.
  12. ↑ "Medicines Patent Pool Nets WHO's Kieny As New Chair". IP Watch. 3 July 2017. Retrieved 9 October 2017.
  13. ↑ "Five Landmark IP Deals Receive Licensing Executives Society's Prestigious 2012 Deals of Distinction™ Awards". lesusacanada.org. Archived from the original on 28 June 2013.
  14. ↑ "AbbVie adds children's AIDS drugs to shared patent pool". Reuters. December 2014.
  15. ↑ Kalil, Tom; Steffen, Robynn (12 December 2013). "Bristol-Myers Squibb and Medicines Patent Pool Increase Access to Critical HIV Drug". whitehouse.gov . Retrieved 16 April 2015– via National Archives.
  16. ↑ HIRSCHLER, BEN (12 July 2011). "Gilead kickstarts patent pool for AIDS drugs". Reuters. Retrieved 16 April 2015.
  17. ↑ "UNAIDS". unaids.org.
  18. ↑ William New (24 February 2015). "Medicines Patent Pool Nails Down Another Key Paediatric Drug". Intellectual Property Watch.
  19. ↑ "ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children | ViiV Healthcare". Archived from the original on 18 June 2013. Retrieved 27 June 2013.
  20. ↑ "GSK's ViiV unit adds new HIV drug to AIDS patent pool". Reuters. April 2014.
  21. ↑ "The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment". Cision. PR Newswire. 24 January 2017. Retrieved 9 October 2017.
  22. ↑ "Press room". MSF USA. Archived from the original on 24 October 2013.
  23. ↑ "The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir". Cision. PR newswire. 21 April 2017. Retrieved 9 October 2017.
  24. ↑ "The Medicines Patent Pool on Janssen's Extension of its Access Policy for Paediatric Medicine Darunavir". Medicines Patent Pool. Archived from the original on 9 October 2017. Retrieved 9 October 2017.
  25. ↑ "Boehringer Ingelheim increases access to the medication for the treatment of HIV/Aids". Boehringer Ingelheim. Retrieved 9 October 2017.
  26. ↑ "Roche-MPP agreement" (PDF). Roche. Archived from the original (PDF) on 7 August 2018. Retrieved 7 August 2018.
  27. ↑ "The Medicines Patent Pool presents new five-year strategy". PR Newswire (Press release). Retrieved 5 August 2018.
  28. ↑ "The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries". Merck.com. Retrieved 17 November 2021.
  29. ↑ "Covid-19: Pfizer to allow developing nations to make its treatment pill". BBC News. 16 November 2021. Retrieved 17 November 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.